Company News

FDA OKs Valeant’s New Acne Treatment

Onexton Gel expected to launch in early 2015.

Author Image

By: Christine Esposito

Editor-in-Chief

Valeant Pharmaceuticals has received approval from the Food and Drug Administration (FDA) for Onexton Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older. Onexton Gel has a favorable cutaneous tolerability profile and contains no surfactants, alcohol or preservatives, according to Valeant, which will launch the treatment in early 2015. Onexton is the fourth product to be approv...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters